Therefore, there has been a growing interest in emergent ovarian cancer biomarkers; thus, the US Food and Drug Administration (FDA) has accepted human epididymal secretory protein 4 (HE4) as a good tumor marker for the clinical setting of OC patients [38]. Here, WFDC2 is linked to ovarian cancer.